PURPOSE: 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-D: -glucose (FDG). PROCEDURES: Fifteen patients with tumor recurrence and four with radionecrosis, determined by clinical course and magnetic resonance imaging results, were studied by dynamic [18F]FLT-PET with arterial blood sampling. A two-tissue compartment four-rate constant model was used to determine metabolic flux (K (FLT)), blood to tissue transport (K (1)), and phosphorylation (k (3)). FDG-PET scans were obtained 75-90 min postinjection. RESULTS: K (FLT) and k (3), but not K (1) or k (3)/k (2) + k (3), reached significance for separating the recurrence from radionecrosis groups. Standardized uptake value and visual analyses of FLT or FDG images did not reach significance. CONCLUSIONS: K (FLT) (flux) appears to distinguish recurrence from radionecrosis better than other parameters, FLT and FDG semiquantitative approaches, or visual analysis of images of either tracer.
PURPOSE:3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-D: -glucose (FDG). PROCEDURES: Fifteen patients with tumor recurrence and four with radionecrosis, determined by clinical course and magnetic resonance imaging results, were studied by dynamic [18F]FLT-PET with arterial blood sampling. A two-tissue compartment four-rate constant model was used to determine metabolic flux (K (FLT)), blood to tissue transport (K (1)), and phosphorylation (k (3)). FDG-PET scans were obtained 75-90 min postinjection. RESULTS: K (FLT) and k (3), but not K (1) or k (3)/k (2) + k (3), reached significance for separating the recurrence from radionecrosis groups. Standardized uptake value and visual analyses of FLT or FDG images did not reach significance. CONCLUSIONS: K (FLT) (flux) appears to distinguish recurrence from radionecrosis better than other parameters, FLT and FDG semiquantitative approaches, or visual analysis of images of either tracer.
Authors: Yuka Yamamoto; Terence Z Wong; Timothy G Turkington; Thomas C Hawk; David A Reardon; R Edward Coleman Journal: Mol Imaging Biol Date: 2006 Nov-Dec Impact factor: 3.488
Authors: D Kahn; K A Follett; D L Bushnell; M A Nathan; J G Piper; M Madsen; P T Kirchner Journal: AJR Am J Roentgenol Date: 1994-12 Impact factor: 3.959
Authors: Alexander M Spence; Mark Muzi; David A Mankoff; S Finbarr O'Sullivan; Jeanne M Link; Thomas K Lewellen; Barbara Lewellen; Pam Pham; Satoshi Minoshima; Kristin Swanson; Kenneth A Krohn Journal: J Nucl Med Date: 2004-10 Impact factor: 10.057
Authors: C Asensio; M J Pérez-Castejón; A Maldonado; R Montz; J A Ruiz; M Santos; I García-Berrocal; J Albert; J L Carreras Journal: Rev Neurol Date: 1998-09 Impact factor: 0.870
Authors: Joanne M Wells; David A Mankoff; Mark Muzi; Finbarr O'Sullivan; Janet F Eary; Alexander M Spence; Kenneth A Krohn Journal: Mol Imaging Date: 2002-07 Impact factor: 4.488
Authors: Finbarr O'Sullivan; Mark Muzi; David A Mankoff; Janet F Eary; Alexander M Spence; Kenneth A Krohn Journal: Ann Appl Stat Date: 2014-06-01 Impact factor: 2.083
Authors: Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen Journal: J Neurooncol Date: 2010-02-24 Impact factor: 4.130
Authors: Laura L Boles Ponto; Yusuf Menda; Kenneth Dornfeld; Timothy J Tewson; G Leonard Watkins; John Sunderland; Michael M Graham; John Buatti Journal: Cancer Biother Radiopharm Date: 2010-06 Impact factor: 3.099
Authors: Mirwais Wardak; Christiaan Schiepers; Magnus Dahlbom; Timothy Cloughesy; Wei Chen; Nagichettiar Satyamurthy; Johannes Czernin; Michael E Phelps; Sung-Cheng Huang Journal: Clin Cancer Res Date: 2011-08-25 Impact factor: 12.531
Authors: Andre D Furtado; Rafael Ceschin; Stefan Blüml; Gary Mason; Regina I Jakacki; Hideho Okada; Ian F Pollack; Ashok Panigrahy Journal: Neuroimaging Clin N Am Date: 2017-02 Impact factor: 2.264
Authors: Michael S Enslow; Lauren V Zollinger; Kathryn A Morton; Regan I Butterfield; Dan J Kadrmas; Paul E Christian; Kenneth M Boucher; Marta E Heilbrun; Randy L Jensen; John M Hoffman Journal: Clin Nucl Med Date: 2012-09 Impact factor: 7.794